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We have identified tissue-specific factors, in human hepatoma cells, that bind specifically to the transcriptional enhancer 
sequence of the human hepatitis B virus (HBV). Two different types of protein factor were found in nuclear extracts 
of hepatoma cells by the gel mobility shift assay. One factor was observed in human hepatoma cells but not in human 
kidney, lung, or vein cells, or in embryonic mouse cells. The other was discovered in both human hepatoma cells and 
human vein cells. DNase I footprint analysis, using the enhancer fragment (164 bp, AccI-SphI) from HBV, revealed that 
two specific sites are recognized by the nuclear factors. These sites contain consensus octamer sequences which have been 
found in many other enhancer elements. These results strongly suggest hat the two nuclear factors found in hepatoma 
cells play key roles in the function of the HBV enhancer. 
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1. INTRODUCTION 
Human hepatitis B virus (HBV) is the etiologic 
agent of acute and chronic liver disease [11. Recent 
epidemiological studies [2,3] have also 
demonstrated that HBV is associated with 
hepatocellular carcinoma. 
genome by the virally encoded reverse transcrip- 
tase [8]. Little is known about the mechanisms of 
control of viral transcription. However, it appears 
that the mechanisms that control synthesis of these 
two viral transcripts are different [5]. There is 
evidence that the 2.1 kb RNA is constitutively ex- 
pressed, whereas the 3.5 kb RNA is inducible [9]. 
The genome of HBV is a partially single- Recently, Shaul et al. [lo] identified an enhancer 
stranded circular DNA with a long or L( - ) strand element in the HBV genome which is located about 
of 3200 bases and a short or S( + ) strand with vary- 450 bases upstream from the promoter for the 
ing degrees of incompleteness [4,5]. Upon infec- 3.5 kb RNA. It is assumed that the enhancer plays 
tion by HBV, two major transcripts are produced a key role in the regulation of gene expression of 
referred to as the 2.1 kb and 3.5 kb RNAs [6,7]. HBV [lo]. Furthermore, studies in vivo of the ex- 
Both transcripts are derived from the L( -) strand. pression of HBV using the ‘CAT’ system revealed 
The 2.1 kb RNA encodes the envelope protein that the enhancer has strict host specificity and 
(HBsAg), the 3.5 kb RNA being the mRNA for the functions only in liver cells of human origin [ 111. 
core protein (HBcAg) and, possibly, for the DNA Therefore, it has been suggested that the enhancer 
polymerase [5]. The 3.5 kb RNA is also believed to requires tram-acting tissue factor(s), present in 
serve as a template for the replication of the viral liver cells, for its activity [ll]. 
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Here, we describe the identification of tissue- 
specific factors in nuclear extracts prepared from 
human hepatoma cells. These factors bind 
specifically to the HBV enhancer sequence. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Human hepatoma cells (HepG2), human kidney cells 
(A-498), human lung cells (CCD-111~) and embryonic mouse 
cells (NIH 3T3) were obtained from the American Type Culture 
Collection (ATCC). Endothelial cells of human vein (passage 
10) were a gift from Dr R.P. Tewari (Southern Illinois Universi- 
ty). Plasmid pAM6 [12], which contains the entire genome of 
HBV linked to pBR322, was obtained from the ATCC. Restric- 
tion enzymes were purchased from US Biochemical Corp. 
Bacterial alkaline phosphatase and T4 polynucleotide kinase 
were obtained from Bethesda Research Laboratories. 
[y-‘*P]ATP was purchased from New England Nuclear. 
2.2. Preparation of the DNA probe 
The probe for the ‘gel mobility shift assay’ was prepared 
from plasmid pAM6 digested with restriction endonucleases 
AccI and SphI. The digestedDNA was treated with bacterial 
alkaline phosphatase and labelled with [y-“‘P]ATP and T4 
polynucleotide kinase. The labelled AccI-SphI fragment, which 
spans 164 bases and contains the entire HBV enhancer sequence 
(see fig.1) [lo], was recovered, after electrophoresis, from a 6% 
polyacrylamide gel by electroelution. 
2.3. Preparation of nuclear extracts 
Cells were grown in Eagle’s minimum essential medium with 
Earle’s balanced salt solution, 2 mM L-glutamine, 10% fetal 
bovine serum, and 100 U/ml each of penicillin G and strep- 
tomycin. Nuclear extracts were prepared as described by 
Dignam et al. [13] and Prywes and Roeder (141, with slight 
modifications. Approx. 5 x lo’-1.5 x 10’ cells were harvested 
and washed with phosphate-buffered saline (PBS, pH 7.4). The 
cells were then suspended in 10 ml buffer A [IO mM Tris-HCl 
@H 7.9), 1.5 mM MgClr, 10 mM KCI, 0.5 mM DTT] and 
allowed to swell at 0°C for 10 min. The cells were collected by 
centrifugation, resuspended in 2 ml buffer A and homogenized 
with a glass Dounce homogenizer (type B pestle). The cell nuclei 
were sedimented by centrifugation at 1000 x g 12 min. The 
nuclei 
‘Cl+ A' reaction, described by Maxam and Gilbert [15], was 
performed using the 5 ’ -end-labelled probe used for the mobility 
shift assay. The DNA samples were analyzed on denaturing 8% 
polyacrylamide gels. 
3. RESULTS 
3.1. Nuclear factors that bind to the HBV 
enhancer 
In order to identify specific cellular factors that 
interact specifically with the HBV enhancer, the 
gel mobility shift assay was performed. The assay 
system is based on the observation that fragments 
of DNA that are bound to proteins migrate 
through acrylamide gels more slowly than free 
fragments of DNA. This system has been suc- 
cessfully used by several investigators to detect 
various nuclear factors required for the regulation 
of transcription [ 16,171. 
The “P-labelled fragment which contains the 
enhancer, and which spans 164 bases (AccI-S’hI, 
fig.1) was mixed with various concentrations of 
nuclear extracts prepared from human hepatoma 
cells (HepG2), and analyzed on polyacrylamide 
gels. As shown in fig.2, two distinct bands (1,II) 
were observed when the gel was subjected to 
autoradiography. Inclusion of SDS and proteinase 
K in the reaction mixture disrupted the formation 
t, 2.lKb RNA - 3SKb RNA 
HBsAg ___ 
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4 II 
Fig. 1. Structure of the genome of HBV (adw). The numbering 
of the nucleotide sequence is based on the data of Onda et al. 
[21]. The enhancer spans the region between nucleotides 1070 
and 1232. This region contains two stretches of the sequences 
which are similar to the consensus sequence of enhancers, 
namely GTGGEG. 
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Fig.2. Detection of enhancer-binding proteins in nuclear 
extracts. 32P-labelled enhancer fragment was mixed with 
various amounts of nuclear extract prepared from H.epG2 as 
described in section 2 (a, 14 pg; b, 7 pg; c, 1.4 /cg; d, 0.7 $g; e, 
0.14pg; f, 0.014pg protein of nuclear extract). Mixtures were 
incubated for 30 min at room temperature and applied to a 6% 
acrylamide gel. The gel was dried and autoradiographed. 
of bands I and II (not shown). This result suggests 
that these bands represent discrete protein-DNA 
complexes. The upper band, which appears around 
the position of the wells, is considered to represent 
non-specific binding of proteins to DNA, since this 
band is generally observed when any DNA probe 
and a high concentration of nuclear extract are 
allowed to react. 
To determine whether these bands are specific to 
the HBV enhancer, we performed a competition 
assay as shown in fig.3. As competitors, plasmids 
pBR322 and pAM6, the latter consisting of the en- 
tire HBV genome carried by pBR322 [12], were 
used. When excess amounts of unlabelled DNA 
from plasmid pAM6 DNA, digested with AccI and 
SphI, were included in the reaction mixture, the in- 
tensity of bands I and II was dramatically de- 
creased (fig.3a, lanes 4-6). However, when the 
same amount of pBR322 DNA, digested with AccI 
and SphI, was used, the intensity of the bands did 
not change (fig.3a, lanes l-3). Furthermore, when 
the unlabelled restriction fragment, generated by 
digestion with AccI and SphI, that spans 164 bases 
and contains the enhancer sequence (see fig. l), was 
added to the reaction mixture as a competitor, the 
intensity of bands I and II decreased significantly 
(fig3b, lanes 3,4). However, addition to the reac- 
tion mixture of a different restriction fragment, 
which spans 250 bp (AccI-AccI, see fig.1) and is 
adjacent to the 5’-end of the enhancer fragment, 
had little effect on the intensity of bands I and II 
(fig.3b, lane 2). These results strongly suggest that 
the binding of the proteins which, with DNA, 
generate bands I and II is specific for the HBV 
enhancer sequence. 
3.2. Tissue specificity of the nuclear factors 
Recently, Jameel and Siddiqui [l l] investigated 
the function of the HBV enhancer using the CAT 
assay system and various cell lines. They found 
that the enhancer sequence functions only in 
human hepatoma cell lines. In order to examine 
the tissue specificity of the factors that are respon- 
sible for the formation of bands I and II, we 
prepared nuclear extracts from various cell lines, 
including human hepatoma, lung, kidney, vein 
cells and embryonic mouse cells. These extracts 
were mixed with the HBV enhancer fragment and 
the resultant protein-DNA complexes were ana- 
lyzed by polyacrylamide gel electrophoresis, as 
described above. As shown in fig.4, only the 
nuclear extract of hepatoma cells contained the 
proteins that could generate both bands I and II. 
However, endothelial cells from human vein con- 
tained a protein factor which comprised only band 
I but not band II. These results suggest that the 
protein factors that are responsible for the forma- 
tion of bands I and II are highly specific to human 
liver cells. 
3.3. DNase I footprint analysis 
In an attempt o identify the binding sites of the 
nuclear factors on the enhancer DNA, footprint 
analysis was performed. Bands I and II, as shown 
in fig.2, were excised from the gel and elec- 
troeluted. The samples were treated with DNase I 
and analyzed by electrophoresis on an 8% 
acrylamide gel. 
As shown in fig.SA, the nuclear factor that com- 
prises band I recognizes a region of 27 bases which 
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Fig.3. Competition for binding to enhancer sequences. (a) ‘*P-1abelled enhancer probe was mixed with 0.7 cg nuclear extract of HepG2 
cells in the presence of either unlabelled pBR322 (l-3) or unlabelled pAM6 (4-6), both of which were digested with AccI and SphI, 
and used as competitors. Concentrations of competitor DNAs were 10 ng (1,4), 100 ng (2,5), and 1 Fg (3,6). Mixtures were incubated 
for 30 min at room temperature and subjected to polyacrylamide gel electrophoresis. The gel was dried and autoradiographed. (b) A 
competition assay similar to that described in (a) was performed but purified fragments of DNA were used as competitors. (1) Control, 
no competitor; (2) 50 ng of 250 bp Accl-AccI fragment (see fig.1) as competitor; (3) 50 ng of 164 bp AccI-SphI enhancer fragment 
(see fig.1) as competitor; (4) 20 ng of 164 bp AC&Q/r1 enhancer fragment. 
spans nucleotides 1176- 1202. This region contains 
a sequence similar to the consensus sequence 
(GTGGEG) of many other enhancers. Similar 
analysis of the DNA in band II revealed that the 
binding region of the other factor spans 
nucleotides 1138-l 154 (fig.SB). This region also 
contains a similar motif to the consensus equence 
of enhancers. However, the orientation of the se- 
quence is opposite to that found in the case of 
band I. 
Fig.4. Tissue specificity of the nuclear factors. Nuclear extracts 
were prepared from human hepatoma (a), human kidney (b), 
human lung (c), human vein (d), and embryonic mouse cells (e). 
0.7/1g protein of each nuclear extract was mixed with 32P- 
enhancer probe and the gel mobility shift assay was performed 
as described in section 2. 
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Fig.5. DNase I footprint analysis of DNA from bands I and II. 
Bands I, II and free form of probe detected by the gel mobility 
shift assay as shown in fig.2 were cut out from the gel, 
electroeluted and treated with DNase I as described in section 
2. As a control, a G+ A reaction was performed according to 
Maxam and Gilbert [IS], using the 5 ’ -end-labelled DNA probe. 
DNA samples were analyzed on 8% denaturing acrylamide gels. 
(1) G + A reaction as a control; (2) free form of DNA probe; (3) 
band I (A) and band II (B). 
4. DISCUSSION 
The nuclear factor that generates band I is pre- 
sent in both hepatoma and vein cells but was not 
detected in any of the other cell lines tested. By 
contrast, the factor comprising band II is present 
only in hepatoma cells. These results, together with 
those of the footprint analysis, suggest that the two 
nuclear factors described here are biochemically 
and, possibly, functionally distinct. However, we 
have recently partially purified these factors and 
found that both are biochemically distinguishable 
but have very similar molecular masses. Therefore, 
we cannot rule out the possibility that the two fac- 
tors are identical but occur in two separate forms, 
possibly covalently modified. 
Here, we have described two different types of Very little is known about the control of gene ex- 
protein factor, which are present in nuclear ex- pression in HBV. It has been demonstrated that, 
tracts of human hepatoma cells and which bind after infection with HBV, the 2.1 kb and 3.5 kb 
specifically to the HBV enhancer sequence. We do RNAs are detectable at almost the same level [9]. 
not as yet know whether these factors mediate However, in patients with integrated viral se- 
enhancer function directly. However, the binding quences, the amount of 2.1 kb RNA is at least 
of these factors to the enhancer is sequence- IO-times greater than that of 3.5 kb RNA [9]. 
specific, and they are present only in a specific Thus, the 3.5 kb RNA appears to be inducible. 
tissue, namely, the hepatoma cell. These results The HBV enhancer is located about 450 bp 
strongly suggest that the newly identified factors upstream from the promotor for the 3.5 kb RNA 
are responsible for the function of the enhancer. [lo]. Therefore, it is assumed that the HBV 
Similar systems have been used to identify several 
nuclear factors that interact with various 
enhancers, such as those of SV40 [18], 
cytomegalovirus [ 191, c-fos gene [14] and im- 
munoglobulin [20]. While further experiments are 
necessary to determine the functional requirements 
of these factors for enhancer activity, the gel 
mobility shift assay and DNase I footprint analysis 
have proved to be useful for the identification of 
these factors. 
The binding site of the nuclear factor to the 
DNA band in band I was identified by footprint 
analysis. The region protected by the protein stret- 
ches from nucleotides 1176 to 1202. This region 
consists of a (X-rich region and an octamer con- 
sensus sequence (GTGGti mG ) which has been 
found in a variety of enhancer elements [181. The 
binding site of the second factor on the DNA in 
band II spans nucleotides 1138- 1154. This site also 
includes a GC-rich region and consensus octamer 
sequence. It is noteworthy that the orientations of 
the consensus equence in the DNA from bands I 
and II are opposite (fig.1). This difference may 
partially explain the orientational independence of 
the enhancer function [ 111. 
353 
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enhancer and the tissue-specific nuclear factors 
described here play key roles in the regulation of 
gene expression, and that these factors and the 
enhancer may also be involved in the oncogenesis 
of hepatocarcinoma. 
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